SCHEMBL3595110

SCHEMBL3595110

COc1ccc(Br)cc1COCC1(c2ccccc2)CCN(C(=O)O)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 8/20 0.48
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.46
SLC6A4 P31645 1/20 0.45
KCNH2 Q12809 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CHRM5 P08912 2/20 0.44
CHRM1 P11229 2/20 0.44
CHRM3 P20309 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
LMNA P02545 2/20 0.42
KCNA3 P22001 1/20 0.42
HSD11B1 P28845 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590159 0.89 TACR1 (0.60) TACR1KDM4EALDH1A1SLC6A4KCNH2
SCHEMBL3587514 0.88 TACR1 (0.48) TACR1SLC6A4CHRM5CHRM1CHRM3
SCHEMBL3596163 0.84 TACR1 (0.45) TACR1ALDH1A1MEN1KMT2ACHRM5
SCHEMBL3596694 0.84 TACR1 (0.46) TACR1SLC6A4KCNH2HSD11B1
SCHEMBL3601967 0.84 TACR1 (0.48) TACR1SLC6A4KCNH2CHRM5CHRM1
SCHEMBL3586504 0.82 TACR1 (0.50) TACR1SLC6A4KCNH2CHRM5CHRM1
SCHEMBL8105902 0.82 TACR1 (0.60) TACR1SLC6A4KCNH2
Hydrochloric Acid SCHEMBL1388687 0.81 TACR1 (0.58) TACR1SLC6A4KCNH2
SCHEMBL3590219 0.80 CHRM5 (0.44) TACR1ALDH1A1SLC6A4KCNH2MEN1
SCHEMBL3592030 0.80 TACR1 (0.43) TACR1ALDH1A1CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383821-B2 NK-1 and serotonin transporter inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-08 US disclosed
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
WO-2007121389-A2 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AS NK-I AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors SLC6A4, TPH1, SLC6A2 TACR1 19/4885KDM4E 2442/4885ALDH1A1 972/4885
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS SLC6A4, TPH1, SLC6A2 TACR1 19/4885KDM4E 2442/4885ALDH1A1 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.